Genomic expression of MSR1 in solid tumors associates with response to anti-PD1 and anti-CTLA4 therapies

Author:

Sanvicente Adrián1,Díaz-Tejeiro Cristina2,Nieto-Jiménez Cristina3,Paniagua-Herranz Lucia3,Cade Igor López4,Balázs Győrffy5,Moreno Victor6,Pérez-Segura Pedro7,Calvo Emiliano8,Ocana Alberto9ORCID

Affiliation:

1. Instituo de investigación Hospital Clinico San Carlos

2. Instituto de investigacion Hospital Clinico San Carlos

3. Insituto de investigación Hospital Clinico San Carlos

4. Instituto de investigación Hospital Clinico San Carlos

5. Semmelweis University 1st Department of Paediatrics: Semmelweis Egyetem I Sz Gyermekgyogyaszati Klinika

6. Fundación Jiménez Díaz: Hospital Universitario Fundacion Jimenez Diaz

7. Hospital Clinico San Carlos Servicio de Oncologia Medica

8. Hospital Universitario HM Sanchinarro

9. Hospital Clínico Universitario San Carlos

Abstract

Abstract Immuno-oncology has gained momentum with the approval of antibodies that have demonstrated clinical activity in different indications. Unfortunately, for anti PD (L)1 agents in monotherapyonly half of the treated population will achieve a clinical response. For other agents like anti-CTLA4 antibodies, no biomarker exists, and tolerability can limit the administration of this compound. In this study, using publicly available genomic datasets, we evaluated the expression of the macrophage scavenger receptor-A (SR-A) (MSR1) and its association with response to check point inhibitors (CPI). MSR1 was mainly and differently expressed in GBM, PAAD, ESCA, STAD, SKCM, OV, KIRC, THYM, HNSC and BRCA, within the tumor microenvironment. MSR1 was associated with the presence of macrophages, dendritic cells (DCs) and neutrophils in most of the studied indications. The presence of MSR1 was associated with macrophages with a pro-tumoral or M2 phenotype and correlated with TIM3 expression. MSR1 predicted favorable overall survival in patients treated with anti-PD1 (HR: 0.56, FDR: 1%, p = 2.6e-05); anti PD-L1 (HR: 0.66, FDR:20%, p = 0.00098) and anti-CTLA4 (HR: 0.37, FDR:1%, p = 4.8e-05). When studying specifically skin cutaneous melanoma (SKCM), we observed a similar effect: anti-PD1 (HR: 0.65, FDR: 50%, p = 0.0072); and anti-CTLA4 (HR: 0.35, FDR:1%, p = 4.1e-05). In a different dataset of SKCM patients, expression of MSR1 predicted clinical response to anti-CTLA4 (AUC: 0.61, p = 2.9e-02). In conclusion, we described the expression of MSR1 in some solid tumors and its association with innate cells and M2 phenotype macrophages. Of note, MSR1 presence predicted response to CPI particularly anti-CTLA4 therapies in different cohorts of patients. Future studies should prospectively explore the association of MSR1 expression and response to anti-CTLA4 strategies in solid tumors.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3